BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37379892)

  • 1. c(RGDfK) anchored surface manipulated liposome for tumor-targeted tyrosine kinase inhibitor (TKI) delivery to potentiate liver anticancer activity.
    Deepak P; Kumar P; Arya DK; Pandey P; Kumar S; Parida BP; Narayan G; Singh S; Rajinikanth PS
    Int J Pharm; 2023 Jul; 642():123160. PubMed ID: 37379892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
    Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
    Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
    Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
    Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma.
    Jagwani S; Jalalpure S; Dhamecha D; Jadhav K; Bohara R
    ACS Biomater Sci Eng; 2020 Sep; 6(9):4969-4984. PubMed ID: 33455290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentapeptide cRGDfK-Surface Engineered Nanostructured Lipid Carriers as an Efficient Tool for Targeted Delivery of Tyrosine Kinase Inhibitor for Battling Hepatocellular Carcinoma.
    Deepak P; Kumar P; Pandey P; Arya DK; Jaiswal S; Kumar A; Sonkar AB; Ali D; Alarifi S; Ramar M; Rajinikanth PS
    Int J Nanomedicine; 2023; 18():7021-7046. PubMed ID: 38046236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
    Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
    Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
    Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
    Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
    Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
    Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
    Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma.
    Zhang X; Lin C; Lu A; Lin G; Chen H; Liu Q; Yang Z; Zhang H
    Drug Deliv; 2017 Nov; 24(1):986-998. PubMed ID: 28644728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
    Yi K; Kong H; Zheng C; Zhuo C; Jin Y; Zhong Q; Mintz RL; Ju E; Wang H; Lv S; Lao YH; Tao Y; Li M
    Biomaterials; 2023 Nov; 302():122349. PubMed ID: 37844429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
    Chen S; Ouyang H; He D; Liu D; Wang X; Chen H; Pan W; Li Q; Xie W; Yu C
    Curr Pharm Des; 2022; 28(25):2113-2125. PubMed ID: 35524673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma.
    Bansal D; Yadav K; Pandey V; Ganeshpurkar A; Agnihotri A; Dubey N
    Drug Deliv; 2016; 23(1):140-6. PubMed ID: 24786484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
    Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
    Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.
    Zheng Y; Kong F; Liu S; Liu X; Pei D; Miao X
    Drug Deliv; 2021 Dec; 28(1):2033-2043. PubMed ID: 34569906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo.
    Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z
    Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.